Table of Contents
- Product Overview & Specifications
- Doxorubicin HCl vs. Similar Agents
- Clinical & Research Applications
- Usage Guidelines & Safety
- Industry Case Studies (2023-2024)
- Request Customized Solutions
Doxorubicin HCl (CAS 25316-40-9) Technical Specifications
Key Parameters
| Parameter | Specification |
|---|---|
| Chemical Name | (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride |
| CAS Number | 25316-40-9 |
| Molecular Formula | C₂₇H₂₉NO₁₁·HCl |
| Purity | ≥98% (HPLC, USP/EP standards) |
| Storage | 2-8°C protected from light |
| Shelf Life | 24 months in original packaging |
Therapeutic Agent Comparison Matrix
| Feature | Doxorubicin HCl | Epirubicin | Daunorubicin |
|---|---|---|---|
| Antineoplastic Spectrum | Broadest (solid & hematologic tumors) | Moderate (breast/ovarian focus) | Narrow (leukemia focus) |
| Cardiotoxicity Risk | High (dose-dependent) | Moderate | High |
| Standard Dosage | 60-75 mg/m² | 100-120 mg/m² | 30-45 mg/m² |
| FDA-Approved Uses | 13 cancer types | 6 cancer types | 4 cancer types |
Oncology Applications & Mechanisms
Clinical Indications
- First-line treatment in metastatic breast cancer (AC regimen)
- Hodgkin’s/Non-Hodgkin’s lymphoma (CHOP protocol)
- Acute lymphoblastic leukemia (hyper-CVAD cycles)
Research Frontiers
- Liposomal encapsulation studies (reduced cardiotoxicity)
- Combination with immune checkpoint inhibitors
- Nano-carrier delivery systems (enhanced tumor targeting)
Operational Protocol & Risk Management
Infusion Guidelines
| Parameter | Requirement |
|---|---|
| Reconstitution | Use only 0.9% NaCl solution |
| Infusion Rate | 30-60 minutes (per 50mg) |
| Incompatible Agents | Heparin sodium, Dexamethasone |
Toxicity Monitoring
- Cardiac: LVEF monitoring every 3 cycles
- Hematologic: ANC counts pre-cycle
- Dermatologic: Palmar-plantar erythrodysesthesia grading
Documented Use Cases (2023-2024)
Case 1: Shanghai Cancer Center
- Application: Triple-negative breast cancer neoadjuvant therapy
- Regimen: Dose-dense AC-T (4 cycles Doxorubicin 60mg/m² + Cyclophosphamide)
- Outcome: 68% pathologic complete response rate
Case 2: Singapore Biotech Ltd.
- Research: pH-sensitive nanoparticle delivery system
- Result: 40% tumor accumulation improvement vs. free drug
- Current Phase: IND-enabling studies
Request Customized Solutions
Contact our oncology specialists for:
- Bulk API procurement (GMP/CEP certified)
- Clinical trial material support
- Formulation development services
Email: info@vivalr.com
Tel: (86) 15866781826
Office Hours: Mon-Fri 8:30 AM – 5:30 PM CST



评论
目前还没有评论。